All In Biotech

Drug Trial Radar · NCT07005713

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants

A Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple- Ascending Doses of BGB-16673 in Patients With Chronic Spontaneous Urticaria and in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

58

Planned (sponsor's estimate)

Start

Jul 19, 2025

Primary completion

Nov 30, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Jun 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1b study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of multiple-ascending doses of tacabrutideg in adults with chronic spontaneous urticaria (CSU) and in healthy participants.

Conditions

  • Chronic Spontaneous Urticaria

Interventions

  • TacabrutidegDrug

    Administered orally

  • PlaceboDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of participants with adverse events (AEs)Time frame: Up to approximately 4 months
  2. Part B: Number of participants with adverse events (AEs)Time frame: Up to approximately 6 weeks
  3. Part A: Maximum observed plasma concentration (Cmax) of tacabrutidegTime frame: Up to approximately 10 weeks
  4. Part A: Minimum observed plasma concentration (Cmin) of tacabrutidegTime frame: Up to approximately 10 weeks
  5. Part A: Time to reach maximum observed plasma concentration (Tmax) of tacabrutidegTime frame: Up to approximately 10 weeks
  6. Part A: Apparent terminal elimination half life (t1/2) of tacabrutidegTime frame: Up to approximately 10 weeks
  7. Part A: Area under the curve (AUC) of tacabrutidegTime frame: Up to approximately 10 weeks
  8. Part A: Apparent oral clearance (CL/F) of tacabrutidegTime frame: Up to approximately 10 weeks
  9. Part A: Apparent volume of distribution (Vz/F) of tacabrutidegTime frame: Up to approximately 10 weeks
  10. Part A: Accumulation Ratio of AUC for tacabrutidegTime frame: Up to approximately 10 weeks
  11. Part A: Accumulation Ratio of Cmax for tacabrutidegTime frame: Up to approximately 10 weeks

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Completed

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Completed

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Completed

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Completed

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China · Completed

  • The Affiliated Hospital of Qingdao University Branch West Coast

    Qingdao, Shandong, China · Recruiting

  • Chengdu Second Peoples Hospital

    Chengdu, Sichuan, China · Completed

  • Hangzhou First Peoples Hospital

    Hangzhou, Zhejiang, China · Completed

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.